Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10383 Phase 1 in healthy volunteers
NCT05429723Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic cough comparing HS-10383 with Placebo (2 arms). Primary endpoint: Safety and Tolerability Evaluation up to 9 days. Status: unknown.
02
Drugs
HS-10383
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT05429723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429723.